Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.80 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312121 | 0.89 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL312545 | 0.86 | SLC6A2 (0.77) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL312785 | 0.84 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL312300 | 0.83 | SLC6A2 (0.83) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL312904 | 0.83 | SLC6A2 (0.73) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL313353 | 0.78 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL312114 | 0.78 | SLC6A2 (0.81) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10108769 | 0.76 | SLC6A2 (0.57) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL312948 | 0.76 | SLC6A2 (0.80) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL13676877 | 0.73 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093285-B2 | Aminopiperidinyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | claimed |
| US-8093285-B2 | Aminopiperidinyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093285-B2 | Aminopiperidinyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093285-B2 | Aminopiperidinyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| CN-101977904-A | Aminopiperidinyl derivatives and uses thereof | HOFFMANN LA ROCHE | 2011-02-16 | — | — | CN | disclosed |
| EP-2268631-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009118254-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118254-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2009-10-01 | — | — | US | disclosed |
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2009-10-01 | — | — | US | disclosed |
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | MAOB, ADORA2B, HTR1B | SLC6A2 8/4885SLC6A3 28/4885SLC6A4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.